Behenic acid

Synopsis

Behenic Acid (Docosanoic Acid): A Comprehensive Reference

1. Identity and Chemical Profile

Nomenclature and Classification

Behenic acid, systematically known as docosanoic acid, is a long-chain saturated fatty acid consisting of a 22-carbon unbranched chain with a carboxylic acid group at one end and the molecular formula C₂₂H₄₄O₂. It belongs to the group of saturated fatty acids — its shorthand notation is 22:0, denoting no double bonds — and is also a member of the group called very-long-chain fatty acids (VLCFAs), defined as fatty acids with 20 or more carbon atoms. Its CAS registry number is 112-85-6, and its PubChem identifier is 8215.

Other synonyms used in the scientific and commercial literature include: docosanoic acid, 1-docosanoic acid, N-docosanoic acid, and docosoic acid. In commerce and cosmetics, it also appears simply as the fatty acid component of "behenate" esters, most notably glyceryl behenate (sold under the trade name Compritol 888 ATO).

Physical and Chemical Properties

In purified form, behenic acid is a white to yellowish waxy solid, with a melting point of 79.95 °C (175.91 °F; 353.1 K) and a boiling point of 306 °C (582.8 °F; 579.15 K) at 60 mm Hg. It is insoluble in water but soluble in organic solvents such as ethanol and ether. Its molecular weight is 340.58 g/mol.

Etymology

Behenic acid is a major component of ben oil (or behen oil), which is extracted from the seeds of the drumstick tree (Moringa oleifera). It is so named from the Persian month Bahman, when the roots of this tree were harvested.

2. Natural Sources and Botanical Origin

Primary Botanical Source: Moringa oleifera

Behenic acid is a major component of Ben oil, also known as behen oil or Moringa oil — first reported by Voelcker A. in 1848 — which is extracted from the seeds of Moringa oleifera and is used in cosmetics. Mature seeds yield 38–40% edible oil called "ben oil" from its high concentration of behenic acid. At 9%, behenic acid is a major component of ben oil.

Behenic acid (C₂₂H₄₄O₂) is the saturated fatty acid typical of Moringa oil, with a content of 2.6 to 4.7%. The oil also contains a dominant fraction of oleic acid and is valued for its stability. The refined oil is clear and odorless, and resists rancidity.

Other Significant Sources

Peanut oil (1–5%), Moringa oleifera seed oil (8%–9%), baru nuts (3.5%–5.8%), dairy fat (traces), pracaxi oil (19%–22.6%), and fully hydrogenated crambe oil (45%–60%) are food sources of behenic acid.

Behenic acid is also present in some other oils and oil-bearing plants, including rapeseed (canola) and peanut oil and skins. It is estimated that one ton of peanut skins contains 13 pounds (5.9 kg) of behenic acid.

Pracaxi oil, obtained from Pentaclethra macroloba seeds, has the highest content of behenic acid and is used in hair conditioners. Behenic acid is also found in some lichens. In olive oil, behenic acid is present at trace levels, from 0.0 to 0.2%. Behenic acid (C22:0) is also detectable among the ten principal fatty acids in coffee.

Behenic acid can also be obtained by the complete hydrogenation of erucic acid (C22:1), which is commonly found in oilseeds of the Cruciferae family. Fully hydrogenated crambe oil, also known as crambe hard fat, is rich in behenic acid and has been suggested as a low-trans-fat alternative.

Common Forms and Preparations

Behenic acid is commercially encountered in several forms and derivative preparations:

Free behenic acid: A white waxy powder or flake, used as a raw material in cosmetics and food applications.
Ben oil / Behen oil: The seed kernels of M. oleifera contain a significant amount of oil (up to 40%) with a high-quality fatty acid composition. The oil is known commercially as "Ben oil" or "Behen oil."
Glyceryl behenate (Compritol 888 ATO): Based on its chemical composition, Compritol 888 ATO is a blend of different esters of behenic acid with glycerol. In pharmaceutical formulations, glyceryl behenate is mainly used as a tablet and capsule lubricant and as a lipidic coating excipient.
Behenyl alcohol: Behenic acid's reduction allows the production of behenyl alcohol, a long-chain fatty alcohol widely used in cosmetics.
Structured lipids (SLs): Engineered fats created by enzymatic or chemical interesterification of oils with crambe hard fat or other behenic acid-rich sources, used in food science research.

3. Traditional and Historical Use

Ancient and Classical Civilizations

The historical record of behenic acid is inseparable from the history of ben oil, its most concentrated natural source. Because of its excellent stability against oxidation and its good properties as a perfume fixative, Moringa oil — also called Behen or Ben oil — was in ancient civilizations the oil most used by producers of unguents for cosmetic and religious uses. This oil was used by cosmetic formulators until the nineteenth century, and its use has been recently "rediscovered."

For centuries, ben oil has been a staple in traditional wellness and beauty rituals, from ancient Egypt to Ayurvedic medicine, where it was known as "Behen Oil" due to its high concentration of behenic acid.

Traditional Indian Medicine (Ayurveda)

Moringa oleifera — known in Sanskrit as Shobhanjana or Sigru, as Sahjan in Hindi, and in Tamil as Murungai Maram — is a small tree from the Indian subcontinent whose pods, roots, bark, flowers, seeds, and fruits are all edible, and it has also become a popular natural leaf powder supplement.

In the Indian subcontinent, in traditional Indian medicine, therapeutically, its leaves, flowers, pods, and seeds are used to treat and prevent diseases such as diabetes, heart disease, anemia, arthritis, liver disease, and respiratory, skin, and digestive disorders. In Ayurveda, the traditional system of medicine in India, Moringa oil has been an integral part of skincare and wellness practices. Valued for its ability to pacify dosha imbalances, it was often employed in massage and skincare routines, promoting not just outer beauty but overall well-being.

Behenic acid also appears in the chemical profile of the seeds of Mucuna pruriens, an Ayurvedic herb known as Kapikachu. In traditional practices of herbal medicine in India and Sri Lanka, M. pruriens is mainly used for the management of neurological diseases, erectile dysfunctions, infertility, arthritis, and scorpion stings. The seeds are reported to have diversified nutritionally and pharmacologically valued chemical constituents, including fatty acids such as palmitic, oleic, stearic, linoleic, linolenic, and behenic acid.

Moringa in African and Southeast Asian Traditions

The rapid growth of Moringa trees in subtropical and tropical areas, even under conditions of prolonged drought, makes this plant a reliable resource to enhance the nutritional status of local populations. Traditional use in these regions has centered on the entire plant — leaves, seeds, roots, and flowers — as a nutritional and medicinal resource. In traditional medicine, the leaves, seeds, flowers, bark, sap, and roots of Moringa oleifera are valued for their antioxidant, anti-inflammatory, antibacterial, anti-cancer, and cardio-protective benefits. The oil expressed from the seeds — rich in behenic acid — has been used topically for skin and hair care across sub-Saharan Africa and South Asia.

It is important to note that traditional uses have generally been attributed to the whole plant or whole oil (with all its constituents, including oleic acid, phytosterols, tocopherols, and flavonoids), rather than to behenic acid as an isolated compound. Despite the relatively diffuse use of Moringa seeds and their oil in traditional medicine, no pharmacological activity study has been conducted on humans specifically attributing effects to behenic acid alone.

4. Key Constituents and Mechanisms of Action

Chemical Structure

Behenic acid is defined as a saturated fatty acid with the chemical formula CH₃(CH₂)₂₀COOH and is categorized as a long-chain fatty acid. Its 22-carbon fully saturated straight chain gives it a high melting point and waxy solid character at room temperature, and profoundly influences its biological behavior.

Intestinal Absorption and Bioavailability

In human physiology, behenic acid exhibits poor intestinal absorption due to its extended chain length, which limits its bioavailability compared to shorter-chain fatty acids and results in increased fecal excretion of lipids when consumed. Upon ingestion, behenic acid is absorbed in the intestine and incorporated into chylomicrons, which are then transported to the liver via the lymphatic system. The metabolism of behenic acid involves its breakdown through beta-oxidation, a process that occurs in the mitochondria.

This long-chain saturated fatty acid acts as a natural inhibitor of pancreatic lipase, seemingly delaying lipid absorption. Behenic acid (C22:0) has been detected in the feces of mice that had chronic ingestion of structured lipids containing up to 6% behenic acid, demonstrating the partial absorption of this fatty acid when consumed long-term.

This low absorption profile has been linked to its potential to elevate serum cholesterol levels in dietary contexts, as demonstrated in metabolic studies where behenic acid supplementation raised low-density lipoprotein cholesterol.

Cholesterol Metabolism

Dietary behenic acid (22:0) is poorly absorbed. Because of its low bioavailability compared with other fatty acids and because of its very long chain length, the effect of dietary behenic acid (behenate) on serum lipid concentrations in humans is assumed to be neutral. However, clinical evidence has challenged this assumption (see Section 5 below).

Anti-Inflammatory Signaling

Even saturated fatty acids including C20:0, C22:0, and C24:0 exhibit the potential to mitigate the occurrence of metabolic disorders, such as diabetes, cardiovascular disease, and cancer, in contrast to shorter even-chain saturated fatty acids (C14:0, C16:0, C18:0), which correlate positively with disease. The proposed mechanism for behenic acid's anti-inflammatory activity involves modulation of the TLR4/NF-κB pathway. Behenic acid mitigated inflammation and insulin resistance in GDM mice by inhibiting activation of the TLR4/NF-κB signaling pathway.

Pancreatic Lipase Inhibition and Postprandial Lipid Handling

One mechanistic explanation for the postprandial effects of behenic acid-containing structured lipids is the inhibition of pancreatic lipase. This long-chain saturated fatty acid acts as a natural inhibitor of pancreatic lipase, seemingly delaying lipid absorption. This is consistent with the physical observation that behenic acid, due to its very high melting point, may remain in a semi-solid state in the intestinal lumen at body temperature, physically limiting enzyme access.

Pharmaceutical Carrier Mechanisms (Glyceryl Behenate)

Glyceryl behenate is used widely as an ingredient for the preparation of lipidic nanoparticles such as solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC). The most common pharmaceutical application of Compritol 888 ATO (glyceryl behenate) is in lipid-based colloidal drug delivery systems such as solid lipid microparticles, solid lipid nanoparticles, and nanostructured lipid carriers. This material presents low cytotoxicity and, due to its amphiphilic properties, the ability to efficiently entrap hydrophilic and lipophilic drugs, thus controlling their release.

5. Scientific Evidence by Area of Use

5.1 Cardiovascular Health and Cholesterol

The key human clinical study on behenic acid and cholesterol was published in the American Journal of Clinical Nutrition (Cater et al., 2001). The objective was to establish the cholesterol-raising potential of behenic acid by comparing the effects on lipid and lipoprotein concentrations of a specially formulated fat enriched with behenic acid with those of palm oil (rich in palmitic acid; 16:0) and high-oleic acid sunflower oil (rich in cis oleic acid; 18:1). In a randomized, crossover, metabolic-ward study, 7 mildly hypercholesterolemic men were fed 3 natural-food diets supplemented with behenate oil, palm oil, or high-oleic acid sunflower oil. Mean serum lipid and lipoprotein concentrations and plasma triacylglycerol fatty acid composition were determined from fasting blood drawn during the final 4 days of each 3-week diet period.

To determine whether behenic acid has cholesterol-raising properties similar to those of palmitate, behenic acid would have only one-third of the cholesterol-raising potential of palmitic acid. Despite its poor absorption, in spite of its low bioavailability compared with oleic acid, behenic acid is a cholesterol-raising saturated fatty acid in humans.

The primary strength of the study was that the diets were fed in a metabolic ward under randomized crossover conditions. The fats used contained 83–90% of fatty acids from behenic acid, palmitic acid, or oleic acid, which permitted a good comparison of the effect of these fatty acids on serum cholesterol concentrations. Very-high-fat diets were used to ensure that sufficient behenic acid was absorbed to detect its cholesterol-raising potential. Each diet period lasted 3 weeks, ensuring that serum lipid and lipoprotein concentrations had reached steady states.

Evidence strength assessment: This is the primary human evidence. The study was small (n=7), used an enriched and atypical behenate oil far exceeding realistic dietary exposures, and was conducted under metabolic-ward conditions. Results may not generalize to typical dietary consumption of behenic acid-containing foods at normal intake levels. Evidence is preliminary and limited in clinical scope.

5.2 Healthy Aging and Circulating Very-Long-Chain Saturated Fatty Acids

A notable prospective epidemiological study examined the relationship between circulating levels of very-long-chain saturated fatty acids (VLSFAs), including behenic acid, and healthy aging. The main outcome was the hazard ratio of an incident unhealthy aging event associated with serial measures of plasma arachidic acid, behenic acid, and lignoceric acid, among 2,680 study participants (mean age 74.7 years). During a median of 6.4 years of follow-up, 2,484 participants experienced an unhealthy event.

Compared with the lowest quintile, levels of behenic acid in the highest quintile of the fatty acid distribution were associated with 15% lower risk of an unhealthy event (HR, 0.85; 95% CI, 0.74–0.97; P for trend = .01) after adjustment for demographic characteristics, lifestyle factors, and clinical conditions. These findings suggest that higher levels of circulating behenic acid and lignoceric acid are associated with lower risk of unhealthy aging events.

Evidence strength assessment: This is observational/epidemiological evidence and cannot establish causation. Circulating VLSFA levels reflect a combination of dietary intake and endogenous metabolism. The association is statistically significant but mechanistic interpretation remains speculative.

5.3 Metabolic Health — Postprandial Inflammation and Lipid Absorption

Multiple preclinical (animal) studies have investigated behenic acid-enriched structured lipids as potential tools to reduce postprandial inflammation and triglyceride absorption.

A high-fat meal can induce a postprandial inflammatory response, characterized mainly by increased serum levels of interleukin (IL)-6 and endotoxemia. A structured lipid rich in behenic acid was developed via enzymatic interesterification of a blend of soy, olive, and fully hydrogenated crambe oil, and its ability to induce postprandial inflammation was evaluated in mice. Triglyceride absorption was reduced after consumption of a meal containing 15% of this structured lipid. The postprandial IL-6, lipopolysaccharide (LPS), C-reactive protein, and insulin levels were similar to those in mice that received a low-fat diet.

A subsequent study in Swiss mice further evaluated palm-free structured lipids. Structured lipids containing 23.79% (SL1), 32.01% (SL2), and 43.87% (SL3) of total saturated fatty acids reduced the absorption of serum triglycerides and appeared to mitigate postprandial inflammation by interleukin-6. A faster gastric emptying rate after consuming SL3 was corroborated by the fecal presence of behenic acid. The results suggest that SLs, free from palm and trans fats, may have the potential to mitigate inflammation, reduce the postprandial response, and lower absorption.

A study comparing a behenic acid-enriched structured lipid (SLBeh) with orlistat for weight loss in obese mice was also conducted. Exploring dietary alternatives to help obese patients lose weight and improve metabolic health, researchers developed a structured lipid rich in behenic acid (SLBeh) obtained by enzymatic interesterification. In this study, the ability of SLBeh to induce weight loss was compared with that of orlistat in obese mice. Obese mice were fed on a high-fat diet formulated with 50% or 100% SLBeh or treated with orlistat.

Evidence strength assessment: All postprandial inflammation and obesity studies are animal (murine) studies only. No human clinical trials have been conducted to test these effects. Evidence is preclinical and preliminary.

5.4 Gestational Diabetes and Insulin Resistance

A 2024 study published in iScience (Cell Press) investigated the effects of behenic acid in a mouse model of gestational diabetes mellitus (GDM). The objective was to investigate the impact of behenic acid (BA) on glucose metabolism, inflammation, and insulin resistance in GDM mice, and to elucidate the underlying molecular mechanism. Daily administration of 10 mg/mL BA during pregnancy effectively ameliorated abnormal glucose metabolism in GDM mice and their offspring and improved birth outcomes in the offspring.

Moreover, BA promoted the proliferation of islet β cells, restored their normal function, and augmented glucose uptake by skeletal muscle cells. Mechanistically, BA mitigated inflammation and insulin resistance in GDM mice by inhibiting activation of the TLR4/NF-κB signaling pathway.

Evidence strength assessment: This is a murine in vivo study. The dose used (10 mg/mL administered daily during pregnancy) is not directly translatable to human clinical use. No human trials exist for this indication. Evidence is preclinical and preliminary.

5.5 Antibacterial Activity

Behenic acid has shown antibacterial efficacy against bacteria including Acinetobacter baumannii, Staphylococcus aureus, and Pseudomonas aeruginosa. These findings are from in vitro laboratory studies. No human clinical data exist to support use for infection treatment.

Evidence strength assessment: In vitro data only. Clinical significance is unknown and no human studies have been conducted.

5.6 Cardiometabolic Risk — Very-Long-Chain Fatty Acids and Lipid Class Interactions

A 2025 prospective cohort study examined the relationship between circulating VLCSFAs (C20:0, C22:0, C24:0) across multiple plasma lipid classes and risk of type 2 diabetes and cardiovascular disease in the EPIC-Potsdam cohort. Very-long-chain saturated fatty acids (VLCSFA) may influence cardiometabolic health differently from other, often detrimental, saturated fatty acids. Evidence remains inconclusive, partly because VLCSFA are metabolically derived from SFA, making it difficult to disentangle their individual effects due to potential confounding of correlated lipids. Prior studies rarely accounted for correlations with other lipids or do not consider VLCSFA-specific lipid classes. Monoglycerides and cholesteryl esters containing VLCSFA were associated with higher risk of both outcomes, highlighting that the metabolic form (lipid class) in which behenic acid circulates may matter greatly.

Evidence strength assessment: Prospective epidemiological; cannot confirm causation. The picture for behenic acid and cardiometabolic risk is complex and inconsistent across lipid classes and study designs.

5.7 Skin and Hair — Cosmetic and Topical Evidence

Commercially, behenic acid is often used to give hair conditioners and moisturizers their smoothing properties. Behenic acid is required to provide a protective barrier against the environment for maintaining good quality of skin. It has emollient, lubricant, and soothing properties that restore the skin's natural oil and promote overall hydration levels.

Behenic acid (5–10% of moringa oil) is a rare long-chain fatty acid that gives moringa oil its exceptional smoothness and oxidative stability. Its high behenic acid content adds smoothness and shine, making moringa oil a popular ingredient in natural hair oils and conditioners.

Evidence strength assessment: Topical cosmetic effects (smoothing, emolliency, occlusivity) are well-documented functionally and commercially. Formal controlled clinical trials on skin or scalp health specifically attributing outcomes to behenic acid as an isolated compound are lacking.

5.8 Drug Delivery (Pharmaceutical Applications)

The behenic acid derivative glyceryl behenate (Compritol 888 ATO) is a well-characterized pharmaceutical excipient with an established evidence base in drug formulation science. It has been investigated for use in the preparation of sustained-release tablets as a matrix-forming agent for the controlled release of water-soluble drugs and as a lubricant in oral solid dosage formulations. It can also be used as a hot-melt coating agent sprayed onto a powder, and it is used widely in cosmetics as a non-comedogenic ingredient that does not clog the oil pores of facial skin.

6. Body Systems and Health Areas of Association

Cardiovascular/lipid system: Influence on serum cholesterol (LDL-C raising at pharmacological doses); association of circulating levels with cardiovascular risk in epidemiological data.
Metabolic/endocrine system: Preliminary evidence in animal models for improvement in insulin resistance, glucose metabolism, and islet β-cell function in gestational diabetes models.
Gastrointestinal system: Inhibition of pancreatic lipase, reduced postprandial triglyceride absorption, and modulated gastric emptying in animal studies.
Immune/inflammatory system: Inhibition of TLR4/NF-κB signaling in murine models; attenuation of postprandial IL-6, LPS, and CRP in mouse studies.
Integumentary system (skin and hair): Emollient, occlusive, and smoothing properties; barrier function support; resistance to oxidative rancidity in cosmetic formulations.
Aging: Epidemiological association of higher circulating behenic acid with lower risk of unhealthy aging events in a prospective cohort.
Microbiology (in vitro): Antibacterial activity against select gram-positive and gram-negative bacteria.

7. Dosage Forms and Dosages Reported in Studies

Behenic acid is not approved or established as a clinical therapeutic agent, and no standardized human dosage exists. The following dosages have been reported in the scientific literature:

Human metabolic-ward cholesterol study (Cater et al., 2001): The fats used contained 83–90% of fatty acids from behenic acid, palmitic acid, or oleic acid. Very-high-fat diets were used to ensure that sufficient behenic acid was absorbed from the diet to detect its cholesterol-raising potential. This represents an extreme, research-only dietary manipulation, not a realistic supplement dose.
Murine gestational diabetes study (2024): Daily administration of 10 mg/mL BA during pregnancy effectively ameliorated abnormal glucose metabolism in GDM mice. This dose is an animal study dose and has not been validated in humans.
Murine postprandial inflammation study (2019): A structured lipid rich in behenic acid was developed. Triglyceride absorption was reduced after consumption of a meal containing 15% of this structured lipid, administered acutely as an oral gavage in mice.
Structured lipid studies with crambe-based SLs (2025): Blends of soybean oil and peanut oil 1:1 wt% were used, with gradual addition of fully hydrogenated crambe to obtain a final behenic acid concentration of 6, 12, 18, and 24%.
Pharmaceutical excipient (glyceryl behenate): Used in tablet formulations as a lubricant and matrix-former; concentrations vary by formulation type. This is not a nutritional dose but a processing dose.

No human clinical trial has established a therapeutic dose range for behenic acid as an isolated dietary supplement.

8. Safety Considerations and Interactions

Cholesterol-Raising Potential

The most substantiated safety concern from published clinical data is the cholesterol-raising effect. In spite of its low bioavailability compared with oleic acid, behenic acid is a cholesterol-raising saturated fatty acid in humans. Behenic acid would have only one-third of the cholesterol-raising potential of palmitic acid. This effect was observed under highly controlled metabolic-ward conditions with diets extremely enriched in behenate oil (83–90% behenic acid), and the extent to which it applies to normal dietary exposures is uncertain.

Poor Bioavailability and Fecal Fat Excretion

Behenic acid exhibits poor intestinal absorption due to its extended chain length, which limits its bioavailability compared to shorter-chain fatty acids and results in increased fecal excretion of lipids when consumed. At high doses, this could theoretically lead to steatorrhea or fat-soluble vitamin malabsorption, as has been observed with other lipase inhibitors, though this has not been specifically documented for behenic acid in humans.

Hepatic Effects

Behenic acid is also known to inhibit the synthesis of fatty acids in rat liver microsomes and to have biological properties such as the ability to induce hepatic steatosis. This finding is from animal/in vitro data and has not been confirmed in human studies. Its relevance to normal dietary intake is unknown.

Peanut and Nut Allergy Considerations

Because behenic acid is present in peanut oil and peanut skins, and commercially derived behenic acid may be sourced from peanut or other nut oils, individuals with nut allergies should be aware of the potential source material. Whether behenic acid as an isolated compound retains allergenic potential from its source material is not established in published literature.

Pharmaceutical Excipient Safety (Glyceryl Behenate)

Glyceryl behenate is used widely in cosmetics as a non-comedogenic (non-pore-clogging) ingredient. It does not clog the oil pores of facial skin. It is classified as generally recognized as safe (GRAS) for its established pharmaceutical uses. This material presents low cytotoxicity.

General Evidence Gap

Despite the relatively diffuse use of Moringa seeds and their oil in traditional medicine, no pharmacological activity study has been conducted on humans. Current evidence does not strongly support any specific health benefit or risk associated with behenic acid consumption in typical dietary amounts. The absence of long-term human safety data for supplemental doses of isolated behenic acid means that interactions with medications, effects in vulnerable populations (pregnant women, individuals with hepatic or lipid disorders), and chronic-use safety remain formally uncharacterized.